Novel peptides and methods and uses thereof for preventing retinal disorders
AssigneeThe Governing Council of the University of Toronto
InventorPaulo Koeberle
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.
Claims37
A method for inhibiting neuronal cell death or dysfunction in an animal or cell in need thereof comprising administering at least one C-terminal peptide, wherein the C-terminal peptide comprises an amino acid sequence as shown in SEQ ID NOs:1-6, 8 or 9 or a variant or analog thereof.
-4. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The method of claim 231, wherein the at least one C-terminal peptide comprises an amino acid sequence as shown in SEQ ID NOs:1, 2, 3, 5, 6, 8 or 9 or a variant or analog thereof and the at least one C-terminal peptide is administered topically in the eye.
(canceled)
A fusion protein comprising a protein transduction domain conjugated to a C-terminal peptide, wherein the C-terminal peptide comprises an amino acid sequence as shown in SEQ ID NOs:1-6, 8 or 9 or a variant or analog thereof.
(canceled)
(canceled)
A composition comprising at least two C-terminal peptides, wherein each C-terminal peptide comprises an amino acid sequence as shown in SEQ ID NOs:1-6, 8 or 9.
(canceled)
(canceled)
(canceled)
-41. (canceled)
Dependencies are inferred from the claim text.